Status:

TERMINATED

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Lead Sponsor:

Kinnate Biopharma

Conditions:

Solid Tumor, Adult

Intrahepatic Cholangiocarcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors ha...

Detailed Description

This is a two-part, open label, multi-center, dose escalation and dose expansion study in participants with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations. Part A (dose escalation) is ...

Eligibility Criteria

Inclusion

  • Provide written informed consent prior to initiation of any study-specific procedures
  • Advanced stage solid tumor
  • Known FGFR2 and/or FGFR3 gene alteration, as confirmed by previous genomic analysis of tumor tissue or ctDNA
  • Measurable or evaluable disease according to RECIST v1.1
  • ECOG performance status 0 or 1
  • Adequate organ function, as measured by laboratory values (criteria listed in protocol)
  • Able to swallow, retain, and absorb oral medications

Exclusion

  • Known clinically-active or clinically-progressive brain metastases from non-brain tumors
  • History and/or current evidence of abnormal calcium-phosphorous homeostasis, ectopic mineralization or calcification, or corneal or retinal disorder/keratopathy
  • GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease
  • Active, uncontrolled bacterial, fungal, or viral infection
  • Women who are lactating or breastfeeding, or pregnant

Key Trial Info

Start Date :

March 29 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 3 2024

Estimated Enrollment :

54 Patients enrolled

Trial Details

Trial ID

NCT05242822

Start Date

March 29 2022

End Date

October 3 2024

Last Update

May 7 2025

Active Locations (21)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (21 locations)

1

Mayo Clinic Arizona

Phoenix, Arizona, United States, 85054

2

UC San Diego Moores Cancer Center

La Jolla, California, United States, 92093

3

Mayo Clinic Florida

Jacksonville, Florida, United States, 32224

4

Sarah Cannon Research Institute - Lake Nona

Orlando, Florida, United States, 32827